Health Products

Taro-Zoledronic acid injection drug, used for osteoporosis and Page's disease, recalled because it may contain particulate matter

· Published by Health Canada · Official notice

Details

Alert type: Public advisory
Category: Health products - Drugs
Product: Taro-Zoledronic acid injection 5mg/100mL (DIN 02415100)
Issue: Health products - Product quality
What to do: Check your product or contact your pharmacist to determine if it is recalled. If you have a recalled product, do not use it and return it to your pharmacy for a replacement product and proper disposal. If you have used the recalled product and have health concerns, contact your healthcare provider. Go to the hospital immediately if you develop difficulty breathing, chest pain or confusion.
Audience: General public
Get told about the next health product recall.

We email or text you when Canada issues a recall that matches what you watch: a brand, a product, an allergen. Most never make the news.

Get health product recall alerts

CA$3.99/mo · cancel anytime

Images

Products

LotExpiry dateDINProduct
JKX1910A
JKX4318A
JKX5541A
HAC2371A
HAC4421A
HAD0156A
April-2023
Aug-2023
Nov-2023
Jun-2024
Nov-2024
Jan-2025
02415100Taro Zoledronic acid injection 5mg/100mL

Issue

Taro Pharmaceuticals Inc. is recalling all lots of Taro-Zoledronic acid injection 5mg/100mL (DIN 02415100) because they may contain particulate matter.

Zoledronic acid is a prescription drug used to treat and prevent osteoporosis and to treat Paget's disease (a condition that disrupts the normal cycle of bone renewal).

If particulate matter is injected into a patient, there is potential for injury, such as inflammation or irritation of the veins, infections at the site of injection or in other parts of the body, allergic reactions, and the formation of blood clots that can move to other parts of the body. In the most serious cases, blood clots could move to the lungs and cause lung damage (pulmonary embolism), which can be permanent or fatal. Patients who have been treated with a recalled drug should go to the hospital immediately if they develop difficulty breathing, chest pain or confusion.

The Department is monitoring the company's recall and will inform the public if any new health risks are identified.

Get told about the next health product recall.
Get health product recall alerts

CA$3.99/mo · cancel anytime